Medical device firm Intact Vascular has closed enrolment in the tack optimised balloon angioplasty II BTK (TOBA II BTK) clinical trial of its Tack Endovascular system to treat patients with critical limb ischemia (CLI).

Tack Endovascular System is an implantable, repair device intended for the treatment of peripheral arterial dissections after balloon angioplasty in above or below-the-knee procedures.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all
“TOBA II BTK has been designed to investigate the safety and efficacy of the Tack Endovascular system in repairing post-angioplasty dissections in the mid/distal popliteal, tibial and peroneal arteries.”

The single arm, prospective TOBA II BTK trial recruited 233 CLI patients, who had standard balloon angioplasty and experienced at least one dissection requiring repair, at 41 sites in the US and Europe.

TOBA II BTK has been designed to investigate the safety and efficacy of the device in repairing post-angioplasty dissections in the mid/distal popliteal, tibial and peroneal arteries.

It involves a combination of the Tack system and plain balloon angioplasty in the arteries below the knee.

Intact Vascular co-founder and chief medical officer Peter Schneider said: “As the first dissection repair device purpose-built for use in these small vessels, we are excited to provide a solution for patients suffering the painful and debilitating effects of critical limb ischemia and who currently do not have adequate treatment options available.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The Tack implant is a novel adjunct therapy that should diminish the chance that these patients will require an amputation.”

The company initiated enrolment in the TOBA II BTK trial in February 2017. The study is part of Intact Vascular’s clinical programme for the Tack Endovascular System.

Currently, the TOBA II trial is evaluating the combination of the Tack Endovascular system with plain angioplasty balloons and the BARD Lutonix drug-coated balloon (DCB) in arteries above the knee.

A separate study, TOBA III, is exploring the combination of the Tack implant with Medtronic’s IN.PACT Admiral DCB. This trial completed enrolment in Europe.